Ignite Creation Date:
2024-05-06 @ 8:16 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02702492
Status:
TERMINATED
Last Update Posted:
2023-01-19
First Post:
2016-03-03
Brief Title:
PAK4 and NAMPT in Patients With Solid Malignancies or NHL PANAMA
Sponsor:
Karyopharm Therapeutics Inc
Organization:
Karyopharm Therapeutics Inc
Study Overview
Official Title:
A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 a Dual Inhibitor of PAK4 and NAMPT in Patients With Advanced Solid Malignancies or Non-Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PANAMA
Brief Summary:
This study will evaluate the safety tolerability and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkins lymphoma NHL Currently enrolling melanoma patients in combination with nivolumab only
Detailed Description:
This is a first-in-human multi-center open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety tolerability and efficacy of KPT-9274 a dual inhibitor of PAK4 and NAMPT in patients with advanced solid malignancies including sarcoma colon lung melanoma etc or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None